Aug 6 (Reuters) - Two more doses of Novo Nordisk's

weight-loss drug, Wegovy, is now available, the U.S.

Food and Drug Administration's updated shortages list showed on

Tuesday.

Several doses of Novo's GLP-1 therapies such as diabetes

drug Ozempic and Wegovy, both chemically known as semaglutide,

have been on the U.S. health regulator's shortage list since

early 2022.

According to the FDA's website, Wegovy's smallest dose of

0.25 milligram (mg) is listed under limited availability, while

all other doses are listed as available. All doses of Ozempic

are available in the United States.

Novo Nordisk said late Tuesday that four of the five dose

strengths of WeGovy are now available in the United States, but

the company will continue to manage shipments of the drug's

initial dose of 0.25 milligram (mg).

Surging demand for therapies such as Wegovy and Ozempic has

led the Danish drugmaker to ramp up supply. Eli Lilly ( LLY ),

which makes rival drugs Mounjaro and Zepbound, has invested

billions of dollars in boosting their production of these drugs.

Last week, all doses of Lilly's weight-loss drug Zepbound

and diabetes drug Mounjaro were listed as available on the drug

shortages list.

Originally developed for diabetes, GLP-1 therapies have

shown to reduce weight by up to 20% in trials. Some analysts

estimate that the market for these therapies could hit $150

billion in revenue by the early 2030s.